* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:RTW vs BLK, BX, KKR: Buyback Yield % Comparison
For the Asset Management subindustry, RTW Biotech Opportunities's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RTW Biotech Opportunities Buyback Yield % vs Asset Management Industry
For the Asset Management industry and Financial Services sector, RTW Biotech Opportunities's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where RTW Biotech Opportunities's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RTW Biotech Opportunities (LSE:RTW) has a Buyback Yield % of 1.64 as of Jul. 08, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on RTW Biotech Opportunities and its competitors. According to the industry distribution chart, RTW Biotech Opportunities ranks #268 out of 761 companies in the Asset Management industry, placing it in the top 35.2%.
Is RTW Biotech Opportunities' Buyback Yield % too high?
RTW Biotech Opportunities' current Buyback Yield % is 1.64. The Asset Management industry median Buyback Yield % is 0.20. RTW Biotech Opportunities' value of 1.64 is 720% above this industry median. Based on the distribution chart, RTW Biotech Opportunities ranks #268 out of 761 companies in the Asset Management industry, which is above the industry midpoint. Overall, RTW Biotech Opportunities has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' Buyback Yield % compare to BLK and BX?
According to the Asset Management industry distribution chart, RTW Biotech Opportunities ranks #268 out of 761 companies for Buyback Yield %. This puts RTW Biotech Opportunities in the upper half of its industry. The industry median Buyback Yield % is 0.20. RTW Biotech Opportunities' value of 1.64 is 720% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for an Asset Management company?
The median Buyback Yield % among Asset Management companies is 0.20, based on 761 companies in the industry. Companies in the top quartile (top 25%) have a Buyback Yield % significantly above this median, while those in the bottom quartile fall well below. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RTW Biotech Opportunities's current Buyback Yield % of 1.64 is 720% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on RTW Biotech Opportunities and its competitors. For the Asset Management industry, the median Buyback Yield % is 0.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RTW Biotech Opportunities's current Buyback Yield % is 1.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current Buyback Yield % of 1.64. The current Buyback Yield % is 1.64 and 720% above the Asset Management industry median of 0.20. RTW Biotech Opportunities' overall GF Score™ is 40/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current Buyback Yield % is 1.64 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
40GF Score
Get the complete analysis for LSE:RTW
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:RTW has been successfully added to your 
